Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Follow-Up Questions
Aditxt Inc 'in CEO'su kimdir?
Mr. Amro Albanna 2017 'den beri şirketle birlikte olan Aditxt Inc 'in Chairman of the Board 'ıdır.
ADTX hissesinin fiyat performansı nasıl?
ADTX 'in mevcut fiyatı $0.2439 'dir, son işlem günde 13.39% increased etti.
Aditxt Inc için ana iş temaları veya sektörler nelerdir?
Aditxt Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Aditxt Inc 'in piyasa değerlemesi nedir?
Aditxt Inc 'in mevcut piyasa değerlemesi $1.2M 'dir
Aditxt Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Aditxt Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 2 tut, 0 sat ve 2 güçlü sat içermektedir
